- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05808595
The Safety and Efficacy of AlphaWave® L-Theanine on Adults Who Experience Moderate Stress on a Regular Basis
A Randomized, Double-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy of AlphaWave® L-Theanine on Adults Who Experience Moderate Stress on a Regular Basis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6B 3L1
- KGK Science Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females between 18 and 65 years of age, inclusive
Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, total endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,
Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
- Intrauterine devices
- Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Individuals with moderate stress as determined by a score of 14 - 26 on the Perceived Stress Scale
- Agrees to maintain current sleep schedule throughout study
- Must have a high school diploma or equivalent and basic computer skills
- Agrees to avoid high caffeine consumption (examples include but not limited to no more than 2 cups/day of caffeinated coffee or tea)
- Agrees to refrain from vigorous physical activity 24-hr prior to study visits
- Agrees to maintain current lifestyle as much as possible including current sleep schedule until the end of the study
- Willingness to complete questionnaires, records and diaries associated with the study, and to complete all clinic visits
- Provided voluntary, written, informed consent to participate in the study
- Healthy as determined by medical history, laboratory results, and as assessed by the QI
Exclusion Criteria:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
- Participants who have a known allergy to the Investigational Product (IP) or Placebo active or inactive ingredients
- Current employment that calls for rotating shift work or shift work that will disrupt normal circadian rhythm in the last 3 weeks
- Travelled across 1 or more time zones in the 3 weeks prior to run-in and/or is anticipating more travel
- Self-reported diagnosis with a stress or sleep disorder as assessed by the QI
- Self-reported diagnosis of a neuropsychiatric and/or cognitive impairment as assessed by the QI
- Self reported colour-blindness
- Type I or Type II Diabetes
- Unstable metabolic disease or chronic diseases as assessed by the QI
- Current or history of any significant disease of the gastrointestinal tract as assessed by the QI
- Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Significant cardiovascular event in the past 6 months as assessed by the QI
- Major surgery in the past 3 months or individuals who have planned surgery during the course of the trial. Participants with minor surgery will be considered on a case-by-case basis by the QI
- Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
- Individuals with an autoimmune disease or are immune-compromised
- History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones symptom-free for 6 months
- Self reported current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Self reported blood/bleeding disorders that will have an effect on safety outcomes as assessed by the QI
- Self-reported alcohol or drug abuse within the last 12 months
- High alcohol intake (>2 standard drinks per day)
- Use of medicinal cannabinoid products, as assessed by the QI
- Chronic use of cannabinoid products (≥2 times/week) and is unwilling to stop use for the duration of the study. Occasional use to be assessed by QI on a case-by-case basis
- Use of tobacco and nicotine-containing products within 60 days of baseline and during the study period
- Current use of prescribed medications which may affect stress, sleep, cognition, and/or mood (see Section 7.3.1)
- Current use of over-the-counter medications, supplements, foods, and/or drinks which may affect stress, sleep, cognition, and/or mood unless willing to undergo the appropriate washout (see Section 7.3.2)
- Clinically significant abnormal laboratory results at screening as assessed by the QI
- Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
- Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
- Individuals who are unable to give informed consent
- Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AlphaWave® L-Theanine
Participants will be instructed to take one capsule twice daily, once in the morning and once in the evening with water with or without food, starting on Day 1.
If a dose is missed participants are instructed to take the missed dose immediately once noticed unless it is noticed within two hours of taking their next dose in which case, participants are instructed to document the missed dose and continue with their regular dosing schedule.
Participants will be advised not to exceed 3 capsules daily.
|
One capsule of AlphaWave® L-Theanine will be taken twice daily for 28 days.
|
Placebo Comparator: Placebo
Participants will be instructed to take one capsule twice daily, once in the morning and once in the evening with water with or without food, starting on Day 1.
If a dose is missed participants are instructed to take the missed dose immediately once noticed unless it is noticed within two hours of taking their next dose in which case, participants are instructed to document the missed dose and continue with their regular dosing schedule.
Participants will be advised not to exceed 3 capsules daily.
|
One capsule of Placebo will be taken twice daily for 28 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The difference in change in stress as assessed by salivary cortisol from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.
Time Frame: Day 0, day 14, day 28
|
Day 0, day 14, day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference in change in stress as measured by the Perceived Stress Scale (PSS) from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.
Time Frame: Day 0, day 14, day 28
|
Day 0, day 14, day 28
|
|
The difference in change in the stress subscale as measured by the Depression Anxiety and Stress Scale (DASS)-21 from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.
Time Frame: Day 0, day 14, day 28
|
Day 0, day 14, day 28
|
|
The difference in change in the depression subscale as measured by the Depression Anxiety and Stress Scale (DASS)-21 from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.
Time Frame: Day 0, day 14, day 28
|
Day 0, day 14, day 28
|
|
The difference in change in the anxiety subscale as measured by the Depression Anxiety and Stress Scale (DASS)-21 from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.
Time Frame: Day 0, day 14, day 28
|
Day 0, day 14, day 28
|
|
The difference in change in the total score measured by the Depression Anxiety and Stress Scale (DASS)-21 from baseline at Days 14 and 28 between AlphaWave® L-Theanine and Placebo.
Time Frame: Day 0, day 14, day 28
|
Day 0, day 14, day 28
|
|
The difference in change in sleep between AlphaWave® L-Theanine and Placebo from baseline at Days 14 and 28, as assessed by the Healthy People Sleep Quality Index (HPSQI).
Time Frame: Days 0, 14, and 28
|
Days 0, 14, and 28
|
|
The difference in change in sleep between AlphaWave® L-Theanine and Placebo from baseline at Days 14 and 28, as assessed by actigraphy readings.
Time Frame: Days 0, 14, and 28
|
Actigraphy readings will include data on sleep duration, sleep onset, wake time, sleep latency, sleep efficiency, sleep stages, arousal count, and sleep score (0-100).
|
Days 0, 14, and 28
|
The difference in change in cognition between AlphaWave® L-Theanine and Placebo from baseline at Days 14 and 28.
Time Frame: Days 0, 14, and 28
|
The difference in change in cognition will be assessed by the Computerized Mental Performance Assessment System (COMPASS): Stroop Test, Simple Reaction Time, and Choice Reaction Time.
|
Days 0, 14, and 28
|
The difference in change in mood between AlphaWave® L-Theanine and Placebo from baseline at Days 14 and 28.
Time Frame: Days 0, 14, and 28
|
The difference in change in mood will be assessed by the Profile of Mood States (POMS) questionnaire.
|
Days 0, 14, and 28
|
Incidence of pre-emergent and post-emergent adverse events (AE) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: 28 days
|
28 days
|
|
Measurement of blood pressure (BP) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 0, day 14, day 28
|
screening, day 0, day 14, day 28
|
|
Measurement of heart rate (HR) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 0, day 14, day 28
|
screening, day 0, day 14, day 28
|
|
Measurement of aspartate aminotransferase (AST) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of alanine aminotransferase (ALT) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of alkaline phosphatase (ALP) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of total bilirubin following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of creatinine following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of electrolytes following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
Electrolytes to be measured include sodium, potassium, and chloride.
|
screening, day 28
|
Measurement of glucose following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of estimated glomerular filtration rate (eGFR) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of white blood cell count (WBC) with differential following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
WBC differentials include neutrophils, lymphocytes, monocytes, eosinophils, and basophils.
|
screening, day 28
|
Measurement of red blood cell count (RBC) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of hemoglobin following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of hematocrit following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of platelet count following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of immature granulocytes following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of nucleated red blood cells (RBC) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of mean corpuscular volume (MCV) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of mean corpuscular hemoglobin (MCH) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of mean corpuscular hemoglobin concentration (MCHC) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
|
Measurement of red blood cell distribution width (RDW) following supplementation with AlphaWave® L-Theanine and Placebo.
Time Frame: screening, day 28
|
screening, day 28
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Crowley, MD, KGK Science Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 22ENCLR01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress
-
Massachusetts General HospitalCompletedStress | Emotional Stress | Psychological Stress | Social Stress | Life StressUnited States
-
University of PadovaRecruitingStress | Stress Disorder | Work Related StressItaly
-
University of California, Los AngelesUniversity of California, San Francisco; Stanford University; California Initiative...Enrolling by invitationStress | Stress, Psychological | Stress, Emotional | Stress, Physiological | Stress ReactionUnited States
-
Dana-Farber Cancer InstituteEnrolling by invitationStress | Post Traumatic Stress Disorder | Work Related StressUnited States
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
University of Sao PauloCompleted
-
Royal Cornwall Hospitals TrustEnrolling by invitationStress | Stress, Psychological | Stress, JobUnited Kingdom
-
Syracuse VA Medical CenterUS Department of Veterans AffairsCompletedEmotional Stress | Psychological Stress | Life StressUnited States
-
Northumbria UniversityVolac International LtdRecruitingStress | Mood | Physiological StressUnited Kingdom
-
Taichung Veterans General HospitalUnknown
Clinical Trials on AlphaWave® L-Theanine
-
Sha'ar Menashe Mental Health CenterStanley Medical Research Institute; Beersheva Mental Health CenterCompleted
-
Butler HospitalCompletedPsychiatric Disorder | Cortical ExcitabilityUnited States
-
Ethical Naturals, Inc.Completed
-
The University of Texas Health Science Center,...CompletedTheanine, (L)-IsomerUnited States
-
University of British ColumbiaCompleted
-
Northumbria UniversityCompletedCognitive Function | MoodUnited Kingdom
-
Sha'ar Menashe Mental Health CenterTirat Carmel Mental Health CenterUnknownSchizophrenia | Schizoaffective Disorder
-
Texas Tech UniversityTexas Tech University Health Sciences CenterCompletedAttention Deficit Hyperactivity DisorderUnited States
-
University of FloridaRecruitingMotor Activity | Cognitive Symptom | Stress Response | Mental Stress | Physiological Stress | Multitasking BehaviorUnited States
-
Ocean Spray Cranberries, Inc.Atlantia Food Clinical TrialsCompletedMood | AttentionUnited States